| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IMPA2 |
| Uniprot No | O14732 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-288aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MKPSGEDQAA LAAGPWEECF QAAVQLALRA GQIIRKALTE EKRVSTKTSA ADLVTETDHL VEDLIISELR ERFPSHRFIA EEAAASGAKC VLTHSPTWII DPIDGTCNFV HRFPTVAVSI GFAVRQELEF GVIYHCTEER LYTGRRGRGA FCNGQRLRVS GETDLSKALV LTEIGPKRDP ATLKLFLSNM ERLLHAKAHG VRVIGSSTLA LCHLASGAAD AYYQFGLHCW DLAAATVIIR EAGGIVIDTS GGPLDLMACR VVAASTREMA MLIAQALQTI NYGRDDEK |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为基于IMPA2重组蛋白相关研究的假设性参考文献示例(建议通过学术数据库核实具体文献)：
1. **《Structural characterization of recombinant human IMPA2 and its role in bipolar disorder》**
- 作者：Smith J, et al.
- 摘要：通过大肠杆菌系统表达并纯化IMPA2重组蛋白，利用X射线晶体学解析其三维结构，揭示了催化活性位点的关键残基，并探讨其与双相情感障碍相关突变的功能关联。
2. **《Optimization of IMPA2 recombinant protein production in mammalian cell systems》**
- 作者：Lee S, et al.
- 摘要：研究在HEK293细胞中优化IMPA2重组蛋白的分泌表达条件，通过糖基化修饰分析提升蛋白稳定性，为神经疾病药物筛选提供高纯度活性蛋白。
3. **《Functional analysis of IMPA2 enzymatic activity in lithium-sensitive signaling pathways》**
- 作者：Chen R, et al.
- 摘要：通过体外酶活实验证明重组IMPA2蛋白对肌醇磷酸底物的特异性水解能力，并发现锂离子对其活性的抑制作用，支持IMPA2作为情绪稳定剂治疗靶点的假说。
4. **《IMPA2 knockout mice and rescue with recombinant protein: Implications for neurodevelopment》**
- 作者：Garcia M, et al.
- 摘要：在IMPA2基因敲除小鼠模型中，外源性重组IMPA2蛋白恢复其突触肌醇代谢功能，改善神经行为缺陷，提示其在神经发育中的关键作用。
---
**备注**：以上文献为模拟示例，实际研究需通过PubMed、Web of Science等平台检索关键词(如“IMPA2 recombinant protein”、“IMPA2 structure/function”)获取。
IMPA2 (Inositol Monophosphatase 2) is a key enzyme in the inositol phosphate signaling pathway, primarily responsible for catalyzing the dephosphorylation of inositol monophosphates, such as inositol 1-phosphate, to generate free inositol. This reaction is critical for maintaining cellular inositol homeostasis, which is essential for synthesizing phosphatidylinositol (PI) and its derivatives—vital components of membrane phospholipids and secondary messengers in intracellular signaling. IMPA2 belongs to the lithium-sensitive family of phosphatases, sharing structural and functional similarities with IMPA1. but differing in tissue-specific expression patterns and regulatory mechanisms. Notably, IMPA2 is highly expressed in the brain, suggesting a role in neurological functions and disorders.
The interest in IMPA2 stems from its connection to bipolar disorder. Lithium, a primary treatment for bipolar disorder, inhibits IMPA2 activity, leading to reduced inositol recycling and modulation of signaling pathways implicated in mood regulation. Dysregulation of IMPA2 has also been linked to other conditions, including cancer and neurodevelopmental disorders, highlighting its broader biomedical relevance.
Recombinant IMPA2 protein is produced using expression systems like *E. coli* or mammalian cells, enabling studies on its enzymatic kinetics, structure, and interactions. Structural analyses (e.g., X-ray crystallography) reveal conserved metal-binding sites and catalytic domains, providing insights into lithium’s inhibitory mechanism. Researchers use recombinant IMPA2 to screen for novel therapeutics, investigate disease mechanisms, and explore its role in cellular processes such as apoptosis and autophagy. Its recombinant form is often engineered with tags (e.g., His-tag) for purification and detection, ensuring high purity and activity for experimental consistency. As a tool in molecular and clinical research, IMPA2 recombinant protein bridges gaps between biochemical understanding and therapeutic innovation.
×
